India's Shasun Turns To China When Protests Block Local Supplies
This article was originally published in PharmAsia News
Shasun Pharmaceuticals has switched from local sources for its API supplies that account for more than half of its revenues, to China in response to protests in Andhra Pradesh that have cut its supplies.
You may also be interested in...
The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.
Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.